Replay: Unleashing The Power Of PROs Throughout Oncology Drug Development

Given the recent draft guidance from the FDA regarding core patient-reported outcomes (PROs) in cancer trials and dose optimization in oncology drug development, the careful gathering and analysis of patient experience data in oncology clinical research are increasingly vital.

Our top eCOA science and oncology research specialists have delved into various scenarios and provided actionable advice for enhancing PRO measurement strategies in oncology drug development, spanning from initial phases to phase III trials.